92 results about "Glucose homeostasis" patented technology

The present invention relates to methods and compounds for regulating glucose metabolism, achieving glucose homeostasis, and decreasing blood glucose levels. Methods and compounds for treating or preventing diabetes, hyperglycemia, and disorders and conditions associated with altered or impaired glucose metabolism are also provided.

Aryl 119 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

This invention relates to a pet food composition for regulating body weight and preventing obesity and related disorders in pets, which comprises as an active ingredient at least one plant or plant extract having the ability to stimulate energy expenditure and/or fat burning. The invention also relates to a method for improving the health of pets, particularly by preventing obesity and metabolic disorders associated with obesity in pets. It also relates to a method for increasing energy expenditure, controlling the glucose homeostasis and improving activity or mobility of the pet.

The present invention encompasses the use of compounds for a novel approach to treat and prevent diseases, conditions, and disorders such as diabetes and ischemic reperfusion injury. Compounds of the invention, including but not limited to BAM15((2-fluorophenyl){6-[(2-fluorophenyl)amino](1,2,5-oxadiazolo[3,4-e]pyrazin-5-yl)}amine), a mitochondrial uncoupler, can improve glucose tolerance, increases cellular oxygen consumption, treat or prevent kidney ischemia reperfusion injury reverse insulin resistance, reverse or treat hyperinsulinemia, and reverse or treat hyperlipidemia. The present invention further provides novel compounds as well as methods for identifying compounds with the same or similar properties as BAM15.

α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using AHSG antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and/or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.

The present invention relates to a Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and a use thereof. Specifically provided are: a composition for appetite control or prevention, improvement, alleviation or treatment of metabolic diseases, containing, as an active ingredient, the strain, a culture liquid thereof and the like, or a B2UM07 protein isolated therefrom; a use of the composition for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases; and a method for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases by using the composition. Therefore, the present invention exhibits effects of weight loss and glucose homeostasis control, from among anti-obesity effects, and influence on brown fat and secretion of an appetite control hormone secretion.

The invention provides methods, compositions, uses of compositions, assays and kits for modulating brown adipose tissue (BAT) in animals and patients with obesity, insulin resistance and perturbed glucose homeostasis are disclosed. Accordingly, methods, compositions, uses of compositions, and kits are useful for the amelioration of pathological conditions characterized by storage of excess energy, insulin resistance and related metabolic syndromes often associated with obesity.

The invention provides a Chinese medicinal preparation for treating diabetes, which is prepared from heterophylly falsestarwort root, gypsum, Indian buead, pollen, dwarf lilyturf tuber, cochinchnese asparagus root, chicken gizzard-membrane, tortoise plastron, dendrobium, turtle shell, medlar, cinnamomvine, common macrocarpium fruit, villous amomum fruit, root of rehmannia, Chinese magnoliavine fruit, dark plum fruit, pangolin, root of straight ladybell, fragrant solomonseal rhizome, common anemarrhena rhizome, dragon's bones and oyster shell according to a conventional Chinese medicament preparation process. The preparation is a pure Chinese medicinal preparation, is used for the treatment of the diabetes and complicating diseases thereof, and has the advantages of having steady therapeutic effect, having no toxic side effect, adjusting the environment in organisms, improving the constitution, relieving the state of insulin resistance, adjusting glycolipid metabolism, strengthening glucose homeostasis and the like.

N-fatty acid-amino acid conjugates and J2 prostanoid-amino acid conjugates are disclosed along with methods for making such conjugates and methods of using these conjugates in the treatment of conditions that involved dysfunctional lipid metabolism, insulin sensitivity, glucose homeostasis, and/or inflammation.

The invention discloses konjac cereal recombined rice beneficial for glucose homeostasis and a preparation method thereof. The konjac cereal recombined rice is prepared from the raw materials in partsby weight: 0-30 parts of konjac glucomannan, 2-5 parts of soybeans, 5-15 parts of oats, 10-30 parts of sorghum, 3-12 parts of red kidney beans, 7-15 parts of black rice, 1-5 parts of proso millet, 15-35 parts of wheat, 1-4 parts of hyacinth beans and 0.3-1.2 parts of monostearin. The konjac cereal recombined rice is reasonable in energy proportion, and energy supply of protein, fat and carbohydrate of the rice is close to the level of natural cereals; the cooking performance is good, the taste is close to that of natural rice, and the common problems of cooking intolerance and soft taste of similar products sold in the market are solved; animal experiments show that multiple glucolipid metabolism indexes can be effectively regulated after long-time eating, glucose homeostasis of bodies isfacilitated, and the konjac recombined rice is the first rice for assisting blood sugar level decreasing function evaluation through animal models. Meanwhile, the product is special in color and hasrich cereal fragrance, the flavor and taste accord with the eating habit of the masses for traditional staple food, and consumers can conveniently eat the rice for a long time.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

The present invention provides reagents and methods for identifying inhibitors of the L-type Ca²⁺ channel β₃ protein, which has been demonstrated to be involved in calcium signaling, insulin secretion, and glucose homeostasis. The invention also provides therapeutics and methods for treating a subject with one or more of diabetes, insulin resistance, impaired insulin secretion, and impaired glucose homeostasis, involving the use of inhibitors of an L-type Ca²⁺ channel β₃ subunit to provide a benefit to the subject.